Some of the previous reports noted that treatment of cancer cells with bortezomib is associated with enhanced apoptosis and reduced expression of survivin [31,32], while other investigators reported that bortezomib-induced apoptosis is accompanied with an induction of survivin expression in human NSCLC cells [33]. Here, BIRC5 is linked to non-small cell lung carcinoma.